Effect of Live Attenuated Influenza Vaccine on Pneumococcal Carriage
J. Rylance, W. A. de Steenhuijsen Piters, S. Pojar, E. Nikolaou, E. German, E. Mitsi, S. Jochems, B. Carniel, C. Solorzano, J. Reine, J. Gritzfeld, M. L. J. Chu, K. Arp, A. D. Hyder-Wright, H. Hill, C. Hales, R. Robinson, C. Lowe, H. Adler, S. Zaidi, V. Connor, L. Lazarove, K. Piddock, I. Wheeler, E. Smith, , D. M. Ferreira
Abstract
The widely used nasally-administered Live Attenuated Influenza Vaccine (LAIV) alters the dynamics of naturally occurring nasopharyngeal carriage of Streptococcus pneumoniae in animal models. Using a human experimental model (serotype 6B) we tested two hypotheses: 1) LAIV increased the density of S. pneumoniae in those already colonised; 2) LAIV administration promoted colonisation. Randomised, blinded administration of LAIV or nasal placebo either preceded bacterial inoculation or followed it, separated by a 3-day interval. The presence and density of S. pneumoniae was determined from nasal washes by bacterial culture and PCR. Overall acquisition for bacterial carriage were not altered by prior LAIV administration vs. controls (25/55 [45.5%] vs 24/62 [38.7%] respectively, p=0.46). Transient increase in acquisition was detected in LAIV recipients at day 2 (33/55 [60.0%] vs 25/62 [40.3%] in controls, p=0.03). Bacterial carriage densities were increased approximately 10-fold by day 9 in the LAIV recipients (2.82 vs 1.81 log10 titers, p=0.03). When immunisation followed bacterial acquisition (n=163), LAIV did not change area under the bacterial density-time curve (AUC) at day 14 by conventional microbiology (primary endpoint), but significantly reduced AUC to day 27 by PCR (p=0.03). These studies suggest that LAIV may transiently increase nasopharyngeal density of S. pneumoniae. Transmission effects should therefore be considered in the timing design of vaccine schedules.\n\nTrial registrationThe study was registered on EudraCT (2014-004634-26)\n\nFundingThe study was funded by the Bill and Melinda Gates Foundation and the UK Medical Research Council.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inflammation induced by influenza virus impairs innate control of human pneumococcal carriage
S. P. Jochems, F. Marcon, … D. M. Ferreira·bioRxiv·Jun 20, 2018
- Intramuscular prime/intranasal boost vaccination to induce sterilizing immunity against influenza A virus infection
Robin Avanthay, Obdulio García-Nicolás, … Gert Zimmer·PLoS PathogensPeer-reviewed·Aug 8, 2024
- Disease modulation by TIV vaccination during secondary pneumococcal infections in influenza-infected mice.
Juan García-Bernalt Diego, Javier Arranz-Herrero, … Michael Schotsaert·Journal of VirologyPeer-reviewed·Dec 29, 2025
- Sequential delivery of LAIV and SARS-CoV-2 in the ferret model can reduce SARS-CoV-2 shedding and does not result in enhanced lung pathology.
K. A. Ryan, K. E. Schewe, … O. Dibben·bioRxiv·Feb 1, 2021
- Bacterial and host factors affecting acquisition of Streptococcus pneumoniae in a murine model
Daniel P Fecko, C L Wu, Jeffrey N. Weiser·Infection and ImmunityPeer-reviewed·Apr 30, 2026
- Influenza Virus Enhances Bacterial Growth in the Lungs through Weakening Capsule Receptor-Mediated Bacterial Capture by Neutrophils
Yujie Fang, Wenxia Ma, … Jing‐Ren Zhang·bioRxiv·Nov 8, 2024